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Summary
Synaptonemal complex protein 3 (SCP3) is a marker for cell transformation that has prognostic
significance in various cancers. However, the prognostic significance of SCP3 has not been
studied in non-small cell lung cancer (NSCLC). To investigate the potential correlation between
SCP3 and various clinicopathologic parameters, we assessed the expression of SCP3 in archival
tumor tissues from 258 NSCLC patients by immunohistochemical staining. By
immunofluorescence, SCP3 was detected in both the cytoplasmic and nuclear fractions of NCI-
H1299 cell. In tumor samples, SCP3 is detected as cytoplasmic expression pattern and observed in
50 (19.4%) clinical samples by immunohistochemical staining. SCP3 expression was correlated
with T status (P=0.008), lymph node metastasis (P=0.010), tumor types (P=0.019) and pleural
invasion (P=0.005). In multivariate analysis of patients with early stage disease, increased SCP3
expression predicted worse overall survival in early stage (stage I–II) with pT1 status (P=0.041).
These results suggest that positive SCP3 expression is a portent of poor outcome, and may be a
potential biomarker in the early stages of the NSCLC for survival and may provide clues in the
identification of patients for adjuvant therapy.
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1. Introduction
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell
lung cancer (NSCLC) being the most common type [1]. NSCLC accounts for more than
80% of all lung cancers. Most patients are diagnosed with advanced disease stage, and
prognosis remains poor [2]. Current guidelines recommend first-line chemotherapy with
platinum-based agents. However, most patients relapse and are evaluated for second-line
therapy after the initial disease control with chemotherapy. Despite major advances in
surgical techniques and new strategies with neoadjuvant treatment, the majority of patients
still succumb to the disease within a year. The high mortality is mainly ascribed to disease
recurrence after lung resection and the lack of effective treatment for advanced disease.
There is a substantial need to develop biomarkers which allow better clinical outcome of
patients with NSCLC. In the current clinical setting, many evaluated, though their utility is
controversial due to their low sensitivity and specificity [3–5]. However, none of them have
yet been incorporated to the clinical practice. Most of the recent efforts have addressed
biomarkers that attempt to predict response to tyrosine kinas inhibitors.
Synaptonemal complex protein 3 (SCP3), the protein encoded by SYCP3, is a DNA-binding
protein and a structural component of the synaptonemal complex, which mediates the
synapsis or homologous pairing of chromosomes during human spermatogenesis [6–8].
Since SCP3 has an essential meiotic function and is involved in genetic stability, the
expression of SCP3 in cells other than germ cells can be associated with a genetic instability
such as aneuploidy. Consistently, SCP3 is preferentially expressed in multiple cancer cells.
For instance, human acute lymphatic leukemias show frequent expression of SCP3 (47%)
[9]. Recently, we also have demonstrated that SCP3 is expressed in human cervical cancer
cells [10]. However, SCP3’s role in NSCLC has not been studied. In the current study, SCP3
protein expression levels were evaluated by immunohistochemistry (IHC), with a tissue
microarray (TMA) of surgically resected samples of NSCLC. The status of SCP3 expression
was then analyzed for an association with clinicopathologic parameters/survival of NSCLC.
2. Materials and methods
2.1. Patients and tumor samples
This study was approved by the ethics committee at Toyama University, and a signed
consent form was obtained from each patient. A total of 258 NSCLC cases were selected
from the pathology case archive of Toyama University Hospital based on the histological
diagnosis, and the quality of the available tissue on the paraffin blocks. None of the patients
received neoadjuvant treatments, and they all underwent complete resections between 1988
and 2004. Smoking histories of 98 cases (38%) were unknown, and survival time and
outcome was available for all patients. The tumors were staged according to the
International Union against Cancer’s tumor-node-metastasis (TNM) classification and
histologically classified and graded according to 2004 World Health Organization (WHO)
guidelines [11]. The follow-up period ranged from 10 to 153 months. No patients received
neoadjuvant therapy. The patients who had relapsed were treated with standard
chemotherapies [12].
2.2. Western blotting
To observe the cellular localization of SCP3 in H1299 cells, cells were subjected to
fractionation using commercial kits (Nuclear/Cytosol Fractionation Kit, Thermo scientific,
Rockford, IL). Equal amounts of nuclear protein and cytosol protein were solubilized in
Laemmli buffer (62.5mM Tris/HCL pH 6.8, 10% glycerol, 2% SDS, 5% mercaptoethanol
and 0.00625% bromophenol blue), boiled for 5 min, and then separated by 12%
polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes. The
Chung et al. Page 2
Hum Pathol. Author manuscript; available in PMC 2014 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
membranes were blocked with 5% nonfat dry milk in TBST (50 mM Tris, 150 mM NaCl,
0.05% Tween-20, pH 7.5) for 1 h at room temperature, and subsequently incubated with
anti-SCP3 (diluted 1:500, BD Bioscience, San Diego, CA), anti-β-actin (diluted 1:2000,
Santa Cruz Biotechnology, Santa Cruz, CA) or anti-H2B (diluted 1:1000, Santa Cruz) in
TBST containing 5% BSA at 4°C overnight, followed by 3 washes in TBST, 5 min per
wash. The membranes were incubated with the appropriate secondary antibodies for 1 h at
room temperature. Immunoreactive bands were visualized by enhanced chemiluminescence
(ECL, Elpis Biotech, Seoul, Korea) reaction.
2.3. Plasmid construction
cDNA encoding the entire coding region of human SCP3 was amplified by PCR with
forward primer 5′-GCTCGAGATGGTGTCCTCCGGAAAAAAG-3′, including a XhoI
restriction site, and reverse primer 5′-GAGAATTCAGAATAACATGGATTGAAGAG-3′
with EcoRI site. The PCR product was digested and subcloned into plasmid EGFP-N1
(Clontech, Palo Alto, CA). The fidelity of expression was confirmed by sequencing. The
nucleotide sequences were determined using the BigDye Terminator Cycle Sequencing
Ready Reaction Kit (Perkin Elmer Biosystems, Foster City, CA) and an ABI PRISM 377
DNA sequencer (Perkin Elmer Biosystems).
2.4. Immunofluorescence
In order to examine the cellular localization of EGFP-SCP3 chimeric molecule, H1299cells
were cultured on 2-well Laboratory-Tek tissue culture chamber slides (BD Falcon, Bedford,
MA) and transfected with 0.4 μg of pEGFP-SCP3 using Lipofectamine™2000 (Invitrogen,
Carlsbad, CA) according to manufacturer’s protocol and incubated for 24 h. The transfected
cells were fixed and permeable with Cytofix/Cytoperm (BD Biosciences) for 20 min at 4°C.
After a wash with PBS following counterstained nuclear with DAPI (100 ng/ml) for 30 min
at room temperature, the localization of SCP3 was observed under a confocal laser scanning
microscope (Carl Zeiss, Thornwood, NJ).
2.5. Tissue microarray construction
TMA was constructed using a TMA arrayer (Pathology Devices, Westminster, MD) as
previously described [13]. For each case, areas with the most representative histology were
selected from review of hematoxylin-eosin (H&E) stained slides. The cylindrical tissue
samples (0.6 mm) were cored from the above described areas in the donor blocks and
extruded into recipient blocks. Multiple 5-μm thick sections were cut with a microtome and
H&E staining of TMA slides were examined at every 50th section to confirm the presence of
tumor cells.
2.6. Immunohistochemistry and scoring
The tissue sections were deparaffinized in xylene and rehydrated through a graded alcohol
series to distilled water. After the deparaffinization and rehydration, antigen retrieval was
performed using a pressure chamber (Pascal, Dako, Carpinteria, CA) with pH 9 Target
Retrieval Solution (Dako). These slides were blocked with hydrogen peroxide/methanol.
After rinsing, the slides were incubated with the anti-SCP3 antibodies overnight at 4°C (BD
Bioscience; dilution 1:50). Target signals were detected with Envision+ kit (Dako). The stain
was visualized using DAB+ kit (diaminobenzidine; Dako) and then lightly counterstained
with hematoxylin, dehydrated in ethanol, and cleared in xylene. The slides were covered and
observed under a light microscope (Axioplot, Carl Zeiss, Jena, Germany).
The SCP3 staining results were scored based on (a) intensity [categorized as 0 (absent), 1
(weak), 2 (moderate), or 3 (strong)] and (b) the percentage of positively stained epithelial
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cells [scored as 0 (0% positive), 1 (1–25%), 2 (26–50%), 3 (51–75%), or 4 (>75%)]. An
overall protein expression score was calculated by multiplying the intensity and positivity
scores (overall score range, 0–12). This overall score for each patient was further simplified
by dichotomizing it to negative (overall score of 0, 1) or positive (score of ≥ 2) [14]. The
rationale for the choice of cutoff for SCP3 protein expression was arbitrary but based on
simple criteria that considered visually discernible differences both the intensity and the
percentage of positive cells. To exclude cores with faint or non-specific staining, we
considered less than 25% of cells stained (the percentage of positivity score of 0 or 1) with
absent or weak staining (the intensity score of 0 or 1) should be negative. Thus the overall
score, the product of these two scores, had to be ≥ 2 to be scored positive.
2.7. Statistical analysis
Statistical analysis was performed using the SPSS for Window (19.0) package (SPSS,
Chicago, IL). We performed survival analysis for all cases. Kaplan–Meier survival analysis
was used to determine the univariate relationship of SCP3 expression with overall survival
times and the survival curves were compared with the log-rank test. Subsequently, we used a
multivariate proportional Cox models and adjusted for the following clinical/pathologic
variables: age at diagnosis, sex, tumor type, differentiation, lymph node metastasis and
pleural invasion. P values were considered significant when they were less than 0.05.
3. Results
3.1. Clinicopathologic features of patients
Clinical and pathologic features of the patients analyzed are summarized in Table 1. The
overall mean age was 65.4 ± 9.0 years for all NSCLC patients and almost 70% of the
patients were male. Tumor staging was available for all 258 cases, and 151 cases were stage
I, 52 cases were stage II, 52 cases were stage III and 3 cases were stage IV. The following
histological types were assigned: 158 adenocarcinomas (61.2%), 93 squamous cell
carcinomas (36.0%) and 7 other types (including 5 adenosquamous and 2 neuroendocrine
carcinomas) (2.7%). Smoking history was available on a small subset of patients (n=160).
3.2. Localization of SCP3 in lung cancer cell
To verify the specificity and capability of the anti-SCP3 antibody for immunohistochemical
staining, we first examined the SCP3 expression pattern using H1299 cells. Nuclear and
cytosolic proteins from H1299 cells were fractionated, and subsequently applied to western
blotting using anti-SCP3 antibody. As shown in Fig. 1A, SCP3 was detected as doublet
bands (30 kDa and 33 kDa) which have been reported in mammals [15]. The lower SCP3
band was constantly detected in the both nuclear and cytosolic fractions whereas the higher
band was mainly detected in the cytosolic fraction. To confirm the nuclear/cytosolic
localization of SCP3, the H1299 cells were transfected with SCP3/EGFP DNA, and, in turn,
examined under a confocal laser scanning microscope after nuclear counterstaining with
DAPI. As shown in Fig. 1B, we observed the dominant localization of SCP3/EGFP in the
perinuclear region of cytoplasm even though the expression of SCP3/EGFP was examined
over all of the H1299 cells. We also observed a similar localization pattern of endogenous
SCP3 after immunofluorescence staining, using a SCP3-specific antibody (data not shown).
These results support the finding of SCP3 in the cytosol, although SCP3 was originally
identified as a nuclear protein in meiotic cells.
3.3. SCP3 protein expression
The expressions of SCP3 in relation to clinicopathologic characteristics were evaluated
(Table 2). SCP3 expressions were evident in 50 (19.4%) out of 258 NSCLC cases and
observed in 27.1% and 13.9% of pT1 and pT2–4 NSCLC, respectively. The expression was
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also detected in 10.9% and 24.1% of NSCLC with and without lymph node metastasis,
respectively. The positivity of SCP3 expression was 20.2% and 16.4% of NSCLC at the
early stage (stage I, II) and the advanced stage (stage III, IV), respectively. SCP3 expression
was correlated with features associated with advanced disease and poor outcome, including
and T status (P=0.008), lymph node metastases (P=0.010), tumor type (P=0.019), and
pleural invasion (P=0.005). All SCP3 staining was observed in the cytoplasm of tumor cells
(Fig. 2). To further validate the SCP3 expression in NSCLC, subgroup analysis was
conducted for various stages and pT status of NSCLC patients (Table 3). The results were
similar between the stages and pT status according to disease severity, as the earlier tumors
showed the higher SCP3 positive rates.
3.4. Prognostic significance of SCP3 expression
We analyzed the prognostic significance of SCP3 expression within subgroups according to
disease severity. Kaplan–Meier estimates of survival for patients with different SCP3
expression are shown in Fig. 3. Multivariate analysis of all the patients failed to identify
SCP3 as an independent predictor of outcome. However, when patients are stratified into
early stage (I or II) and tumor size (pT1), SCP3 expression was significantly associated with
worse prognosis (P=0.014) with an even stronger association in stage IA patients (P=0.007).
In early stage with pT1 subgroup, a Cox univariate proportional hazards analysis showed
that SCP3 positivity, sex, tumor type, and tumor differentiation were related to poor overall
survival. On multivariate analysis, SCP3 positivity (hazard ratio = 2.54 (95% CI, 1.03–
6.25), P=0.041) was an independent predictor of poor prognosis (Table 4).
4. Discussion
In this study, we validated the use of SCP3, for the first time, as a potentially relevant
NSCLC prognostic marker. Our findings demonstrated that SCP3 expression seems to be
associated with poorer prognosis and is an independent prognostic factor for survival in
patients with NSCLC. Although SCP3 is suspected to be involved in stabilizing
chromosomes during spermatogenesis, the exact role of SCP3 in cancer cells has not been
proven [6, 8]. Ectopic expression of SCP3 can be a cause of genetic instability of cancer
cells, leading to abnormality such as aneuploidy. It has been reported that patients who
benefit from a surgical resection for NSCLC with aneuploid DNA content prove to have a
higher risk of death [16]. In this context, the role of SCP3 in genetic instability of NSCLC
needs to be explored. In addition to the possibility of SCP3 as a factor disrupting genetic
stabilization, SCP3 can be an apoptosis-associated multiple resistant factor for various
cancer therapeutic agents. In a previous study, we demonstrated that the activation of PI3K/
AKT mediated by overexpression of SCP3 in tumor cells leads to the upregulation of
antiapoptotic proteins, resulting in the immune resistant phenotype [10]. SCP3-mediating
AKT activation also appears to be highly associated with resistance of tumor cells to cancer
drugs [17]. These data suggest that SCP3 could be a novel prognostic marker in NSCLC.
SCP3 is a meiosis-specific protein and identified as a nuclear protein in meiotic germ cells
[18]. However, we observed SCP3 expression in the cytoplasm of the lung cancer cells by
IHC. In addition, we demonstrated by western blot analysis that SCP3 subcellular
localization is altered in cancer cells (Fig. 1). The altered subcellular localization could be a
cancer-specific phenomenon. Jiao et al suggest that aberrant nucleocytoplasmic localization
of the retinoblastoma (RB) tumor suppressor protein, disrupt normal cell differentiation
programs and accelerate the cancer progress via aberrant nucleocytoplasmic transport,
related with tumor progression [19]. In addition, it is well known that the function of tumor
suppressor proteins (APC, p53, Smad4, and p27kip1) can be inactivated by mislocalization
[20–23]. Therefore, the ectopic expression of SCP3 in NSCLC is not a surprising
observation and may be linked to the cancer progression by an unknown mechanism.
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In the current study, we showed, through IHC, that SCP3 protein expression is significantly
associated with T status (P=0.008), lymph node metastases (P=0.010), tumor type
(P=0.019), and pleural invasion (P=0.004). Although the percentage of patients expressing
SCP3 in NSCLC is not high (19.6% of all cases), it is expressed in an increased percentage
of early stage patients (30.2% in stage IA patients). Within this group of early stage disease
(stage IA, pT1), multivariate analysis suggests SCP3 has the best discriminative value with
reference to survival.. Early diagnosis of NSCLC is thought to be important as surgical
treatment, in early stage disease, could provide patients the best chance of cure. In this
circumstance, early biomarkers are urgently needed to allow better clinical management of
patients with NSCLC.
Some of biomarkers have been reported to indicate poor prognosis of early stage NSCLC
patients. In retrospective study of 411 patients with surgically resected NSCLC, Yoo et al.
showed that polymorphisms in the CASPASE genes had poor survival in early-stage
NSCLC [24]. In another recent study, Dhillon et al. reported that mTOR staining provided a
new biomarker for poor outcome in early stage NSCLC [25]. In current study, the patients
with SCP3 positive cases have a worse prognosis and therefore are better candidates for
adjuvant chemotherapy. SCP3 may play a role as an indicator that specialized treatment is
necessary for early stage NSCLC patients.
In conclusion, the current study has demonstrated the potential value of SCP3 as a useful
prognostic marker for NSCLC, especially when it is applied to early stage disease. Although
SCP3 cannot provide all of the necessary information for optimal NSCLC prognosis, our
results suggest an association between SCP3 expression and NSCLC. Therefore, with
further research assessing its potential clinical usefulness, SCP3 may play a role as an
indicator of adjuvant chemotherapy and lead to a new strategy for early stage NSCLC
patients.
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Fig. 1.
Synaptonemal complex protein 3 (SCP3) localization in a lung cancer cell line. (A) Nuclear
and cytoplasmic fractions from H1299 cells were analyzed by western blot analysis using a
SCP3 antibody. H2B and beta-actin were used as indexes for nuclear and cytoplasmic
fractions, respectively. (B) Confocal fluorescent microscopy was used to further evaluate the
distribution of SCP3 in H1299 cells 24 h after transfection of SCP3/EGFP DNA.
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Fig. 2.
Representative images of immunohistochemistry for synaptonemal complex protein 3
(SCP3). Negative - demonstrating a lack of SCP3 expression (A); Positive - cytoplasmic
staining in adenocarcinoma (B) and squamous cell carcinoma (C). Boxed regions are
displayed at high magnification in the bottom panel. All photomicrographs ×100.
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Fig. 3.
Kaplan-Meier survival analysis ofNSCLC according to SCP3 expression. (A) In early stage
(≤ stage II) with pT1 group, patients with positive SCP3 expression (median survival, 87
months) showed significantly worse survival than those with negative SCP3 expression
(median survival, 134 months). (B) Stage IA group with positive SCP3 expression (median
survival, 87 months) had a significantly worse patients’ survival time than those with
negative SCP3 expression (median survival, 138 months).
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Table 1
Clinicopathologic characteristics of 258 patients with non-small cell lung cancer
Category No. of cases % of total
Sex
 Male 180 69.8
 Female 78 30.2
Age at time of diagnosis (years)
 Average (mean ± SD) 65.4 ± 9.0
 < 50 15 5.8
 50 – 59 45 17.4
 60 – 69 106 41.1
 ≥ 70 92 35.7
Smoking status
 Never 85 32.9
 Ever 75 29.1
 Unknown 98 38.0
Stage
 IA 86 33.3
 IB 65 25.2
 IIA 9 3.5
 IIB 43 16.7
 IIIA 48 18.6
 IIIB 4 1.5
 IV 3 1.2
T status
 pT1 107 41.5
 pT2 121 46.9
 pT3 27 10.4
 pT4 3 1.2
Lymph node metastasis
 pN0 166 64.3
 pN1 47 18.2
 pN2 44 17.1
 pN3 1 0.4
Tumor type
 Adenoca. 158 61.2
 SCC 93 36.0
 Adenosquamous 5 1.9
 Neuroendocrine 2 0.8
Differentiation
 Well 108 41.8
 Moderate 97 37.6
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Category No. of cases % of total
 Poor 49 19.0
Pleural invasion
 Negative 173 67.1
 Positive 85 32.9
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Table 3
SCP3 expression in various stages and pT status of NSCLC
No. of cases % of total
SCP3 expression
Negative Positive
Stage IA 86 33.3 60 (69.8%) 26 (30.2%)
Stage IA + IB 151 58.5 114 (75.5%) 37 (24.5%)
Stage I+Stage II 203 78.7 162 (79.8%) 41 (20.2%)
Stage I+Stage II+Stage III 255 98.8 205 (80.4%) 50 (19.6%)
Stage I+Stage II+Stage III+Stage IV 258 100 208 (80.6%) 50 (19.4%)
pT1 107 41.5 78 (72.9%) 29 (27.1%)
pT1+pT2 228 88.4 181 (79.4%) 47 (20.6%)
pT1+pT2+pT3 255 98.8 205 (80.4%) 50 (19.6%)
pT1+pT2+pT3+pT4 258 100 208 (80.6%) 50 (19.4%)
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Table 4
Survival analysis of the patients in early stage (stage I and II) with pT1 (n=96) by Cox proportional hazards
Variables
Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
SCP3
 Negative 1 0.014* 1 0.041*
 Positive 2.90 (1.24 – 6.75) 2.54 (1.03 – 6.25)
Sex NS
 Female 1 0.027*
 Male 3.39 (1.14 – 10.04)
Tumor type NS
 Adenoca. 1 0.005*
 SCC 3.31 (1.43 – 7.66)
Differentiation NS
 Well 1 0.001*
 Moderate - Poor 6.05 (2.04 – 17.96)
Lymph node metastasis NS NS
Pleural invasion NS NS
Age (years) NS NS
*Significant at the level of p<0.05
Adenoca.; adenocarcinoma, SCC; squamous cell carcinoma.
HR; hazard ratio, CI; confidence interval, NS; not significant.
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